Drug company Mylan disclosed in a regulatory filing this week that it has reached a $30 million agreement-in-principle to resolve the Securities and Exchange Commission’s investigation alleging securities violations for disclosures surrounding its popular EpiPen.

Learn More
Already a member? Sign in to an existing account.

Jaclyn Jaeger is a freelance contributor to Compliance Week after working for the company for 15 years. She writes on a wide variety of topics, including ethics and compliance, risk management, legal,...